Summer Intern 2027, DMPK Bioanalysis
Vertex Pharmaceuticals
Summary
The Vertex DMPK Bioanalysis Intern is an 11-week experiential training program for students enrolled in a degree program, providing meaningful experience in Preclinical Sciences.
Job description
Your Impact
The Vertex DMPK Bioanalysis Intern is an 11-week experiential training program for students enrolled in a degree program, providing meaningful experience in Preclinical Sciences.
What you will be doing
The DMPK bioanalysis group develops assays to support preclinical study analysis for multiple therapeutic modalities and programs. This position will be directly involved in the development of a ligand-binding assay and will provide experience in bioanalytical method development, including assay design, optimization, and data analysis.
Key Responsibilities
- Support the development and optimization of a ligand-binding assay.
- Plan and conduct experiments with guidance from the bioanalytical team.
- Evaluate assay performance, including sensitivity, precision, and reproducibility.
- Analyze results, troubleshoot technical challenges, and recommend next steps.
- Document methods, experiments, and results in accordance with relevant bioanalytical guidelines and Vertex documentation policies.
- Present findings and progress updates to the team.
Qualifications
- Currently enrolled in a bachelor's or master's degree program in biochemistry, biology, biotechnology, chemistry, pharmacology, or a related life-sciences field.
- No prior industry experience required; at least one laboratory course or research experience involving biochemical or biological experiments is expected.
- Ability to perform basic laboratory techniques, including accurate pipetting, preparing solutions and serial dilutions.
- Foundational understanding of protein-ligand interactions, assay controls, and basic data analysis.
- Familiarity with ligand-binding assays is helpful but not required.
- Ability to record and analyze experimental data using Microsoft Excel or Graphpad Prism.
- Experience with Meso Scale Discovery platforms is a plus.
- Strong attention to detail, clear documentation and communication, and the ability to troubleshoot experiments with guidance.
- Legal authorization to work in the United States, now and in the future.
- Must be enrolled in an advanced degree program if graduating before May 2027.
- Must be available to work full-time, 40 hours per week from May - August 2027.
Program Details
- Full-time, paid internship $23.00 - $32.00 USD/hour
- Program Dates: May - August 2027
- Application Deadline: January 15th, 2027
Requirements
- Currently enrolled in a bachelor's or master's degree program in biochemistry, biology, biotechnology, chemistry, pharmacology, or a related life-sciences field
- At least one laboratory course or research experience involving biochemical or biological experiments
- Ability to perform basic laboratory techniques including accurate pipetting, preparing solutions and serial dilutions
- Foundational understanding of protein-ligand interactions, assay controls, and basic data analysis
- Ability to record and analyze experimental data using Microsoft Excel or Graphpad Prism
- Strong attention to detail, clear documentation and communication, and ability to troubleshoot experiments with guidance
- Legal authorization to work in the United States, now and in the future
- Must be enrolled in an advanced degree program if graduating before May 2027
- Available to work full-time, 40 hours per week from May - August 2027
Benefits
- Gym access
- Group exercise classes
- Subsidized commuter benefits
- Free breakfast
- Career development opportunities
- Social events
- Medical, Dental & Vision
- Paid time off
- Educational assistance
- Student loan repayment
- 401(k)
Company overview
Vertex Pharmaceuticals is a global biotechnology company headquartered in Boston, Massachusetts, founded in 1989. The company specializes in discovering, developing, and commercializing transformative medicines for serious diseases, with a primary focus on cystic fibrosis (CF). Vertex has pioneered breakthrough therapies including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which collectively treat approximately 90% of CF patients. Beyond CF, the company has expanded its portfolio to include treatments for sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and has robust clinical pipelines in APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency. Vertex employs approximately 6,100 people globally and maintains research facilities in San Diego, California, and Milton Park, Oxfordshire, England. The company is publicly traded on NASDAQ (VRTX) and is recognized as one of the industry's top workplaces, consistently earning accolades for its innovative culture and patient-focused approach to drug development.